Allurion Technologies (Allurion Technologies) Forward Dividend Yield % : 0.00% (As of May. 26, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Allurion Technologies Forward Dividend Yield %?

As of today (2024-05-26), the Forward Annual Dividend Yield of Allurion Technologies is 0.00%.

As of today (2024-05-26), the Trailing Annual Dividend Yield of Allurion Technologies is 0.00%.

ALUR's Forward Dividend Yield % is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 1.96
* Ranked among companies with meaningful Forward Dividend Yield % only.

Allurion Technologies's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Allurion Technologies's Forward Dividend Yield %

For the Medical Devices subindustry, Allurion Technologies's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allurion Technologies's Forward Dividend Yield % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Allurion Technologies's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Allurion Technologies's Forward Dividend Yield % falls into.

Allurion Technologies Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Allurion Technologies (NYSE:ALUR) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Allurion Technologies Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Allurion Technologies's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Allurion Technologies (Allurion Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Allurion Technologies Inc (NYSE:ALUR) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

11 Huron Drive, Natick, MA, USA, 01760

Website

Allurion Technologies Inc is a leading medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.

Executives

Omar Ishrak	director	710 MEDTRONIC PKWY, MS LC300, MINNEAPOLIS MN 55432
Nicholas Sheridan Lewin	director	3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Krishna K. Gupta	director, 10 percent owner	307 HARVARD ST, CAMBRIDGE MA 02139
Christopher J Geberth	officer: Chief Financial Officer	11 HURON DRIVE, SUITE 200, NATICK MA 01760
Michael R Davin	director	C/O CYNOSURE, INC., 5 CARLISLE ROAD, WESTFORD MA 01886
Larson Douglas Hudson	director	11 HURON DRIVE, SUITE 200, NATICK MA 01760
Benoit Chardon	officer: Chief Commercial Officer	11 HURON DRIVE, SUITE 200, NATICK MA 01760
Shantanu Gaur	director, officer: Chief Executive Officer	11 HURON DRIVE, SUITE 200, NATICK MA 01760
Ram Chuttani	officer: Chief Medical Officer	11 HURON DRIVE, SUITE 200, NATICK MA 01760